Brief: Gracell Biotechnologies To Present Updated Clinical Data On Bcma/Cd19 Dual-Targeting Car-T Gc012f For Relapsed/Refractory Multiple Myeloma At 2022 Asco Annual Meeting
27/05/2022 24:51
May 26 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES TO PRESENT UPDATED CLINICAL DATA
ON
BCMA/CD19 DUAL-TARGETING CAR-T GC012F FOR RELAPSED/REFRACTORY
MULTIPLE MYELOMA AT 2022 ASCO ANNUAL MEETING
Source text for Eikon: ID:nPnbP8ZWya
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27